BACKGROUND & AIMS: The functional involvement of the endocannabinoid system in modulation of pancreatic inflammation, such as acute pancreatitis, has not been studied to date. Moreover, the therapeutic potential of cannabinoids in pancreatitis has not been addressed. METHODS: We quantified endocannabinoid levels and expression of cannabinoid receptors 1 and 2 (CB1 and CB2) in pancreas biopsies from patients and mice with acute pancreatitis. Functional studies were performed in mice using pharmacological interventions. Histological examination, serological, and molecular analyses (lipase, myeloperoxidase, cytokines, and chemokines) were performed to assess disease pathology and inflammation. Pain resulting from pancreatitis was studied as abdominal hypersensitivity to punctate von Frey stimuli. Behavioral analyses in the open-field, light-dark, and catalepsy tests were performed to judge cannabinoid-induced central side effects. RESULTS: Patients with acute pancreatitis showed an up-regulation of cannabinoid receptors and elevated levels of endocannabinoids in the pancreas. HU210, a synthetic agonist at CB1 and CB2, abolished abdominal pain associated with pancreatitis and also reduced inflammation and decreased tissue pathology in mice without producing central, adverse effects. Antagonists at CB1- and CB2-receptors were effective in reversing HU210-induced antinociception, whereas a combination of CB1- and CB2-antagonists was required to block the anti-inflammatory effects of HU210 in pancreatitis. CONCLUSIONS: In humans, acute pancreatitis is associated with up-regulation of ligands as well as receptors of the endocannabinoid system in the pancreas. Furthermore, our results suggest a therapeutic potential for cannabinoids in abolishing pain associated with acute pancreatitis and in partially reducing inflammation and disease pathology in the absence of adverse side effects.
BACKGROUND & AIMS: The functional involvement of the endocannabinoid system in modulation of pancreatic inflammation, such as acute pancreatitis, has not been studied to date. Moreover, the therapeutic potential of cannabinoids in pancreatitis has not been addressed. METHODS: We quantified endocannabinoid levels and expression of cannabinoid receptors 1 and 2 (CB1 and CB2) in pancreas biopsies from patients and mice with acute pancreatitis. Functional studies were performed in mice using pharmacological interventions. Histological examination, serological, and molecular analyses (lipase, myeloperoxidase, cytokines, and chemokines) were performed to assess disease pathology and inflammation. Pain resulting from pancreatitis was studied as abdominal hypersensitivity to punctate von Frey stimuli. Behavioral analyses in the open-field, light-dark, and catalepsy tests were performed to judge cannabinoid-induced central side effects. RESULTS:Patients with acute pancreatitis showed an up-regulation of cannabinoid receptors and elevated levels of endocannabinoids in the pancreas. HU210, a synthetic agonist at CB1 and CB2, abolished abdominal pain associated with pancreatitis and also reduced inflammation and decreased tissue pathology in mice without producing central, adverse effects. Antagonists at CB1- and CB2-receptors were effective in reversing HU210-induced antinociception, whereas a combination of CB1- and CB2-antagonists was required to block the anti-inflammatory effects of HU210 in pancreatitis. CONCLUSIONS: In humans, acute pancreatitis is associated with up-regulation of ligands as well as receptors of the endocannabinoid system in the pancreas. Furthermore, our results suggest a therapeutic potential for cannabinoids in abolishing pain associated with acute pancreatitis and in partially reducing inflammation and disease pathology in the absence of adverse side effects.
Authors: Mert Erkan; Jörg Kleeff; Irene Esposito; Thomas Giese; Knut Ketterer; Markus W Büchler; Nathalla A Giese; Helmut Friess Journal: Oncogene Date: 2005-06-23 Impact factor: 9.867
Authors: Mohab M Ibrahim; Frank Porreca; Josephine Lai; Phillip J Albrecht; Frank L Rice; Alla Khodorova; Gudarz Davar; Alexandros Makriyannis; Todd W Vanderah; Heriberto P Mata; T Philip Malan Journal: Proc Natl Acad Sci U S A Date: 2005-02-10 Impact factor: 11.205
Authors: Enrico Lupia; Alberto Goffi; Paolo De Giuli; Ornella Azzolino; Ornella Bosco; Enrico Patrucco; Maria Cristina Vivaldo; Marco Ricca; Matthias P Wymann; Emilio Hirsch; Giuseppe Montrucchio; Giorgio Emanuelli Journal: Am J Pathol Date: 2004-12 Impact factor: 4.307
Authors: Ihsan Ekin Demir; Kristina Kujundzic; Paulo L Pfitzinger; Ömer Cemil Saricaoglu; Steffen Teller; Timo Kehl; Carmen Mota Reyes; Linda S Ertl; Zhenhua Miao; Thomas J Schall; Elke Tieftrunk; Bernhard Haller; Kalliope Nina Diakopoulos; Magdalena U Kurkowski; Marina Lesina; Achim Krüger; Hana Algül; Helmut Friess; Güralp O Ceyhan Journal: Proc Natl Acad Sci U S A Date: 2016-12-16 Impact factor: 11.205
Authors: Ravil R Petrov; Maria E Ferrini; Zeina Jaffar; Charles M Thompson; Kevan Roberts; Philippe Diaz Journal: Bioorg Med Chem Lett Date: 2011-08-03 Impact factor: 2.823
Authors: Nicholas J Zyromski; Abhishek Mathur; Henry A Pitt; Terence E Wade; Sue Wang; Deborah A Swartz-Basile; Andrew D Prather; Keith D Lillemoe Journal: J Gastrointest Surg Date: 2009-02-19 Impact factor: 3.452
Authors: Christoph W Michalski; Florian E Oti; Mert Erkan; Danguole Sauliunaite; Frank Bergmann; Pal Pacher; Sandor Batkai; Michael W Müller; Nathalia A Giese; Helmut Friess; Jörg Kleeff Journal: Int J Cancer Date: 2008-02-15 Impact factor: 7.396